7
Total investments
1
Early stage
4
Mid stage
1
Late stage
7y
Years active
Portfolio
7 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
2024
At Enable Medicine, we index biological data into highly detailed maps of human disease. This atlas is utilized to guide novel drug target discovery, identify biomarkers of therapeutic response, and develop optimal treatment strategies. Our lab in Menlo Park, California, generates high-parameter biological datasets, and our cloud-based operating system allows researchers to organize, process, query, and analyze this data at scale. Taken together, our platform unlocks the ability to search biology, where complex questions about human disease can be asked and answered for the first time.
We build and provide these capabilities to our network of leading academic institutions and pharmaceutical companies around the world. Our collaborative research spans numerous indications, with a core focus on unmet needs in oncology and autoimmune diseases. We advance science by accelerating data generation, methods development, research insights, and high-impact publications. Our interdisciplinary team of scientists, engineers, researchers, and investors focuses on decoding biological systems to make drug discovery, development, and patient care more deterministic. Come join us on our mission to decipher biology and meaningfully improve the way patients are treated.
Board Member
2022
Epitel is empowering clinicians, patients, and caregivers who live with and care for neurological disorders through wearables and powerful AI.
Investor
2021
Attune Neurosciences is a clinical-stage medical device company dedicated to improving human health and performance through clinically-proven, non-invasive neurostimulation products.
Board Member
2021
SimBioSys is a technology company on a mission to deploy Computational Oncology to transform decision making and patient experience in Cancer Care. By virtualizing cancer, clinicians and patients are empowered with a better understanding of the disease and can assess all available options computationally to truly individualize treatment.
Board Member
2021
BRAINBox Solutions™ multi-modality approach is led by the leaders in the industry. It will include blood biomarker panels available on a point of care instrument and standard laboratory systems, as well as neurocognitive testing, to provide objective evidence of injury and prediction of patient recovery.
Board Observer
2019
Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.
Experience · 10 entries
All (10)
Investments (7)
Founder (2)
Board (6)
2025
2024
Board Member
2024
At Enable Medicine, we index biological data into highly detailed maps of human disease. This atlas is utilized to guide novel drug target discovery, identify biomarkers of therapeutic response, and develop optimal treatment strategies. Our lab in Menlo Park, California, generates high-parameter biological datasets, and our cloud-based operating system allows researchers to organize, process, query, and analyze this data at scale. Taken together, our platform unlocks the ability to search biology, where complex questions about human disease can be asked and answered for the first time.
We build and provide these capabilities to our network of leading academic institutions and pharmaceutical companies around the world. Our collaborative research spans numerous indications, with a core focus on unmet needs in oncology and autoimmune diseases. We advance science by accelerating data generation, methods development, research insights, and high-impact publications. Our interdisciplinary team of scientists, engineers, researchers, and investors focuses on decoding biological systems to make drug discovery, development, and patient care more deterministic. Come join us on our mission to decipher biology and meaningfully improve the way patients are treated.
2022
Board Member
2022
Epitel is empowering clinicians, patients, and caregivers who live with and care for neurological disorders through wearables and powerful AI.
2021
Investor
2021
Attune Neurosciences is a clinical-stage medical device company dedicated to improving human health and performance through clinically-proven, non-invasive neurostimulation products.
Board Member
2021
SimBioSys is a technology company on a mission to deploy Computational Oncology to transform decision making and patient experience in Cancer Care. By virtualizing cancer, clinicians and patients are empowered with a better understanding of the disease and can assess all available options computationally to truly individualize treatment.
Show all 10 entries ↓
Investment activity
2019–2025 · 7 investments
Recent (last 2 years)Earlier
